Annals of Oncology Advance Access originally published online on July 27, 2006
Annals of Oncology 2006 17(10):1533-1538; doi:10.1093/annonc/mdl154
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2006 European Society for Medical Oncology
urogenital tumors |
A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium
1 Department of Oncology, Aarhus University Hospital, Denmark
2 Klinik für Urologie and Kinderurologie, Universität des Saarlandes, Germany
3 Institut Paoli-Calmettes, Marseille, France
4 Department of Oncology, Helsinki University Central Hospital, Finland
5 Department of Oncology, Herlev University Hospital, Denmark
6 Eli Lilly and Company, Indianapolis, IN, USA
*Correspondence to: Prof H. von der Maase, Department of Oncology, Aarhus University Hospital, DK-8000 Aarhus C, Denmark. Tel: +45-89-49-25-31; Fax: +45-89-49-25-30; E-mail: maase{at}as.aaa.dk
Background: Both pemetrexed and gemcitabine have single-agent activity in bladder cancer, but the combination of these two drugs has not been previously evaluated for safety and efficacy in this disease. Thus, the objectives in the current study were to determine overall response rate (ORR), progression-free survival, overall survival and safety and toxicity in chemonaive patients with locally advanced and/or metastatic transitional cell carcinoma of the urothelium.
Patients and methods: Gemcitabine 1250 mg/m2 was administered over 30 min i.v. on days 1 and 8, and pemetrexed 500 mg/m2 over 10 min i.v. on day 8 after gemcitabine, every 21 days.
Results: Sixty-four patients were enrolled, 11 female and 53 male, median age 65 years (range 38–81), median WHO performance status of 1. Visceral metastases were present in 55% of patients. ORR among 47 patients evaluable for response was 28% (95% CI 16% to 43%) and ORR for the intention-to-treat population was 20% (95% CI 11% to 32%) with three CR and 10 PR. Median response duration was 11.2 months and median overall survival 10.3 months (95% CI 8.1–14.6 months). CTC grade 3/4 hematologic toxicities included anemia (19%), thrombocytopenia (9%), neutropenia (38%), febrile neutropenia (17%) and neutropenic sepsis (3%). Grade 3/4 non-hematologic toxicities included elevated transaminases (12%), dyspnea (8%), fatigue (8%) and stomatitis (5%). There was one toxic death due to neutropenic sepsis.
Conclusions: The combination of pemetrexed and gemcitabine had a manageable safety profile. However, efficacy was apparently not superior to that of single-agent gemcitabine.
Key words: bladder cancer, gemcitabine, pemetrexed, urothelial cancer
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Sweeney, D. F. Bajorin, and C. N. Sternberg Muscle-invasive Bladder Cancer: What Have We Learned and What's New on the Horizon? ASCO Educational Book, January 1, 2008; 2008(1): 200 - 208. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G Di Lorenzo and S De Placido Re: Perabo FGE and Muller SC. New agents for treatment of advanced transitional cell carcinoma. Ann Oncol 2007; 18: 835-843. Ann. Onc., June 1, 2007; 18(6): 1118 - 1118. [Full Text] [PDF]
|
|